Evofem Biosciences Q3 2024 operating loss narrows to $2.4M; acquires SOLOSEC, licenses Phexxi in Middle East

Evofem Biosciences, Inc.

2024-Q3 EPS reported -$0.09 revenue$12,259,000

Net product sales $4.5M in Q3 2024, down 12% YoY from $5.1M; operating loss improved 31% to $2.4M.
Net loss attributable to common stockholders $2.4M ($0.02/sh) vs net income $66.0M ($15.34/sh) in Q3 2023 due to prior-year debt extinguishment gain.
Acquired global rights to SOLOSEC (secnidazole) 2g oral granules, FDA-approved for BV and trichomoniasis, relaunched as single-dose treatment.
Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; UAE regulatory submission on track by year-end 2024.
Aditxt invested $5.0M since May 2024, including $1.3M in Q3 and $2.7M in October 2024, under amended merger agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.